{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000612","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.940719+00:00","generated_at":"2026-06-25T21:06:35.742455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Edgewise Therapeutics reports Q1 2022 net loss of $14.7M; cash at $265.8M","bullets":["Net loss of $14.7M ($0.30 per share) vs. $12.7M in the prior quarter.","Cash, equivalents and marketable securities of $265.8M; expected to fund operations through 2024.","Completed enrollment of ARCH open-label study of EDG-5506 in BMD; Phase 2 trials planned for 2022.","R&D expenses $11.1M, up $2.0M from prior quarter; G&A flat at $3.7M.","Advanced preclinical EDG-002 program targeting hypertrophic cardiomyopathy; IND-enabling studies in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000612","json":"https://secwatch.observer/filing/0001157523-22-000612.json","markdown":"https://secwatch.observer/filing/0001157523-22-000612.md","text":"https://secwatch.observer/filing/0001157523-22-000612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/0001157523-22-000612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/a52714442.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:06:35.742455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}